ClinicalTrials.gg
TerminatedNCT05879744Updated Oct 22, 2026

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

A Phase 1 interventional study of CLN-978 in NHL and NHL, Relapsed, Adult, sponsored by Cullinan Therapeutics Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Cullinan Therapeutics Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Strategic business decision

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 5 months ago, and no results have been posted to the registry.
Updated Oct 22, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States — 137 open to participants now, 252 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.

Enrollment
1,278th of 1,377
3 · median 35
Started
2023
with 49 others
Phase 1
528 of 1,599
47 open now
Registered
1,506th of 1,599
by date

Among the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is the 1,278th largest by enrollment of the 1,377 interventional ones that give a count, is one of 50 that started in 2023, is one of 528 in phase 1, and was the 1,506th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

137 of the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:

132 more — sign in →

All 137 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, or all of them as a file.
02

Study summary

CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).

03

Conditions studied

  • NHL
  • NHL, Relapsed, Adult

Keywords

  • Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) PS ≤ 2
  • Documented diagnosis of one of the below CD19+ B-cell neoplasms according to WHO classification (Swerdlow et al., 2016) or WHO classification 2008:

    1. Diffuse large B-cell lymphoma - de novo or transformed
    2. High-grade B-cell lymphoma
    3. Primary mediastinal large B-cell lymphoma
    4. Follicular lymphoma
    5. Mantle cell lymphoma
    6. Marginal zone lymphoma (nodal, extranodal, or mucosa-associated)
  • , progressive, and/or refractory disease after at least 2 .
  • For Part B expansion cohorts:

    1. Cohort B1: R/R DLBCL that has relapsed after at least 2 prior therapies including a CD20 monoclonal antibody and anthracycline.
    2. Cohort B2: R/R FL (grade 1-3a) that has relapsed after at least 2 prior therapies including CD20 monoclonal antibody and an alkylating agent.
    3. Cohort B3: Other R/R B-NHL.
  • defined as ≥1 measurable nodal lesion (long axis >1.5 cm and short axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on computed tomography (CT) scan or magnetic resonance imaging (MRI) AND baseline fluorodeoxyglucose-positron emission tomography (FDG-PET) scan demonstrating positive lesion(s) compatible with CT- or MRI-defined anatomical tumor sites.
  • Laboratory parameters including the following:

    1. Lymphocyte count \< 5 x 10\^9/L
    2. count ≥ 75 x 10\^9/L
    3. ≥ 1.0 x 10\^9/L; growth factor support allowed in cases of documented bone marrow involvement
    4. ≥ 9 g/dL, with or without transfusion
    5. ≥ 45 mL/min
    6. Total ≤ 1.5 × (ULN), except patients with confirmed Gilbert's Syndrome
    7. (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN (unless attributed to hepatic involvement by lymphoma)

Exclusion criteria

Exclusion Criteria:

  • Primary CNS lymphoma or known CNS involvement by lymphoma at study screening
  • Known past or current other than the inclusion diagnosis
  • Known cardiac disease
  • Significant central nervous system disease
  • Prior organ allograft
  • Confirmed history or current disorder or other disease requiring ongoing immune suppression
  • Active Virus (HCV), Virus (HBV), or known (HIV) infection
  • within 28 days of the first dose of CLN-978, during treatment, and until the end of last dose of CLN-978
  • Known active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection, including coronavirus disease of 2019 (COVID-19) infection, at the time of enrollment or within 7 days of the first dose of CLN-978.
  • Prior treatment with any of the following:

    1. HSCT
    2. Autologous HSCT within 30 days prior to the first dose of CLN-978
    3. Chimeric antigen receptor T cell therapy (CAR-T) within 30 days prior to the first dose of CLN-978
    4. Any CD19 x CD3 T cell engager (TCE)
    5. Unconjugated CD19 monoclonal antibody ≤ 4 weeks prior to the first dose CLN-978
    6. Radio-conjugated or CD19 antibody-drug conjugate ≤ 12 weeks prior to the first dose CLN-978
    7. Investigational or standard of care monoclonal antibodies, chemotherapy, or other investigational agent ≤ 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of CLN-978
    8. Radiation therapy (XRT), with the exception of focal treatment for symptom control, ≤ 4 weeks of the first dose of CLN-978
  • Woman of who is pregnant, breast-feeding, or plans to become pregnant
  • Male patients who plan to father a child or donate sperm within 120 days of last study drug administration
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Part A Dose Escalation

    Patients with R/R B-NHL treated with CLN-978 in dose escalation cohorts

    Drug: CLN-978

  • Experimental
    Part B Dose Expansion

    Patients with R/R DLBCL, R/R FL and other R/R B-NHL treated with CLN-978 at a dose selected from the Part A Dose Escalation arm.

    Drug: CLN-978

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of CLN-978 based on AEs, AESIs, and SAEs

    Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs); incidence of dose interruptions and delays

    Time frame: 24 months

  2. Define dose regimen for CLN-978

    Dose-limiting Toxicities (DLTs)

    Time frame: 24 months

Secondary outcomes

  1. Assess preliminary efficacy of CLN-978 by overall response in patients with selective histologies of R/R B-NHL

    Overall response rate (ORR)

    Time frame: 24 months

  2. Assess preliminary efficacy of CLN-978 by complete response in patients with selective histologies of R/R B-NHL

    Complete response (CR)

    Time frame: 24 months

  3. Assess preliminary efficacy of CLN-978 by duration of response in patients with selective histologies of R/R B-NHL

    Duration of response (DOR)

    Time frame: 24 months

  4. Select PK parameters of CLN-978: AUC

    Area under-the-concentration-time curve of CLN-978

    Time frame: 24 months

  5. Select PK parameters of CLN-978: Cmax

    Maximum concentration of CLN-978

    Time frame: 24 months

  6. Select PK parameters of CLN-978: Half-life

    Half-life of CLN-978

    Time frame: 24 months

  7. Immunogenicity of CLN-978 and potential impact on drug exposure

    Incidence of anti-drug antibodies to CLN-978

    Time frame: 24 months

07

Study locations

6 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • City of Hope
    Duarte, California 91010, United States
  • Winship Cancer Institute at Emory University
    Atlanta, Georgia 30322, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2023 to primary completion in Jun 2024, 12 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Nov 2026 → Jun 2024 and completion Apr 2027 → Jun 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2023
First posted
May 30, 2023
StartActual
May 31, 2023
Primary completionActual
Jun 1, 2024was Nov 2026
CompletionActual
Jun 1, 2024was Apr 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Strategic business decision
changed Oct 22, 2026
Primary completion
Nov 2026→Jun 1, 2024 (actual)
Oct 22, 2026
Study completion
Apr 2027→Jun 1, 2024 (actual)
Oct 22, 2026
Enrollment
90 (estimated)→3 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Active, not recruiting→Terminated
    Why stopped Strategic business decision
    Primary completion Nov 2026→Jun 1, 2024 (now actual)
    Study completion Apr 2027→Jun 1, 2024 (now actual)
    Enrollment 90 (estimated)→3 (actual)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05879744
Lead sponsor
Cullinan Therapeutics Inc.
Responsible party
Sponsor
First posted
May 30, 2023
Start date
May 31, 2023
Primary completion
Jun 1, 2024
Completion
Jun 1, 2024
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978

Start the discussion